Imaging biomarkers in prostate cancer: role of PET/CT and MRI. - Wikidata - awgldk - TriplyDB

Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

http://www.wikidata.org/entity/Q38321182

about

Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.PET imaging for lymph node dissection in prostate cancer.(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.Clinical significance of prostate 18F-labelled fluorodeoxyglucose uptake on positron emission tomography/computed tomography: A five-year review.Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors.Using magnetoferritin nanoprobes for both nuclear and magnetic-resonance imaging.(68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.Molecular imaging of cholinergic processes in prostate cancer using ¹¹C-donepezil and ¹⁸F-FEOBV.Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.Current status and future perspectives of PET/MRI hybrid imaging PET/MRI in gynecological tumors Prostate cancer recurrence: can PSA guide imaging?

P2860

Q28074669-32E32265-7C21-4F92-A63B-83A295F31ED9 Q31003607-68973E64-55BD-4D22-BCFD-7F3A57BC627B Q36596346-A2B7C872-35C3-4F65-BFFC-FB8C57F7A933 Q37496697-B73809A7-B99D-4C85-8C4C-03E61AE4EE41 Q38564109-500133FE-8475-4529-986E-20B044462784 Q38983526-820916FC-60CF-4BCE-90E6-28A156CA176E Q39699773-08809849-A5E4-41D2-9AF8-6D186E76EE5D Q44453209-91E16EF8-8295-474A-A296-DB15683276BD Q47099403-C5D68AAA-DF74-4CAC-8545-29DFDCC838F8 Q47833074-E9822C0E-1D6E-4518-A41C-24B7847BCF68 Q51309917-379D4C20-C509-4CC4-A47E-7079CD1AF65B Q52990377-C38761E6-1642-40D3-A7DE-24198E9FB881 Q52993610-148F948D-8E99-492F-98E9-C59D5349ED26 Q55603215-4F6D9EF6-2473-4BB2-927F-814D22D3AFE2 Q57780515-3D6CFEB7-D1F2-4B17-929C-7B5DCA617CD5 Q57780526-EB8EFD90-271D-41AE-A5F3-4E811373A3B7 Q57780533-4B67983A-C922-4067-9B79-DABC3AF0CBEA

P2860

Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

http://www.wikidata.org/entity/Q38321182

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

@en

type

label

Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

@en

prefLabel

Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

@en

P1433

Q38321182-FE4DD85B-B581-4F2D-88A5-6001C2FE460C

P1476

Q38321182-E8DB061C-CB52-46DD-85A9-DCD50F7F8DA9

P2093

Q38321182-06CBA8F8-5AB2-4F13-9FAC-558033A7FF5B

Q38321182-12D6C621-722D-4F26-8F77-3FB708629DDB

Q38321182-255DB8AC-DC03-42A1-98E3-C431BDA33968

Q38321182-60C716E0-662F-4ECC-AB97-890318840B5E

Q38321182-8A374646-3F24-4D17-8605-428AA4B0FA19

Q38321182-995DAFFF-81EC-4D76-B12C-34A24D6D6D32

Q38321182-B724D675-9773-4388-B4B2-B379F3622F5F

Q38321182-CF0391F3-A5D8-474B-BDDB-9C95AD56D079

P2860

Q38321182-0235D0F1-3A85-4130-A1D2-8D6A0EEFD586

Q38321182-026C0E53-6B35-49F9-BDD6-9019BED69B64

Q38321182-0EA2A53E-F1D3-4A73-A042-D37D29B45C48

Q38321182-15BB5D44-810F-49F6-85FF-A3A992F5FB42

Q38321182-17334EE8-2D0A-416A-AB51-E096D2FBEADB

Q38321182-18108CE7-5C52-42F5-86FB-B91D740955B3

Q38321182-188D4845-81A7-46ED-B6C5-EDE76D31BAA6

Q38321182-1A2957EB-B162-424C-BDA8-190F30259144

Q38321182-1CA5EE2B-F2AE-4CE3-9335-BB4E4A768F7D

Q38321182-1F07EA8D-F2D8-4F00-90CB-F6CE222B7970

P2888

Q38321182-5DEF7A06-0C6F-4EB8-85A1-8A6FAB602E3E

P304

Q38321182-AB7B6A03-4FCA-4AD9-A6C5-99E857265C96

P31

Q38321182-F259E347-9A81-4845-BE88-3E2475113B58

P356

Q38321182-B468BA58-FD58-4825-ABE2-B5B543812215

P433

Q38321182-24CCCC33-9629-49C7-8CF1-4E62785025CE

P478

Q38321182-737AD723-DD0D-4A27-AF00-2674E8BCB414

P50

Q38321182-0F190E40-1C57-42FB-B503-1F67634A7AAB

Q38321182-62A65459-AB3A-4444-8E30-E3A7703A3AEF

Q38321182-940FE3FA-4317-4DED-B21E-E4A138220A0E

Q38321182-BFBE2746-B290-4DC8-B6A6-F492AAFCED2F

Q38321182-D3F3FFFD-2603-47DC-81F1-A87215E6F446

P577

Q38321182-47F8771B-AE83-4E12-8BE7-B22B9B7BB733

P5875

Q38321182-9915A852-AB2F-4A0F-924F-F08257185BC9

P698

Q38321182-7F1E99E9-7BDE-4477-94FB-94FAA5A742E5

P921

Q38321182-254D7439-70D5-4A5C-A8FF-A9F63A379BC9

P356

S00259-014-2982-5

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Imaging biomarkers in prostate cancer: role of PET/CT and MRI

@en

P2093

A Briganti

http://www.w3.org/2001/XMLSchema#string

C Nanni

http://www.w3.org/2001/XMLSchema#string

F Barchetti

http://www.w3.org/2001/XMLSchema#string

F Montorsi

http://www.w3.org/2001/XMLSchema#string

G Gandaglia

http://www.w3.org/2001/XMLSchema#string

L Gianolli

http://www.w3.org/2001/XMLSchema#string

P Castellucci

http://www.w3.org/2001/XMLSchema#string

V Panebianco

http://www.w3.org/2001/XMLSchema#string

P2860

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer.

Natural history of progression after PSA elevation following radical prostatectomy.

Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations

Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.

Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer.

Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

[11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study.

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

Advanced imaging for the early diagnosis of local recurrence prostate cancer after radical prostatectomy.

Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.

P2888

s00259-014-2982-5

P304

644-655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-014-2982-5

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Margarita Kirienko

P577

2015-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271022967

http://www.w3.org/2001/XMLSchema#string

P698

25595344

http://www.w3.org/2001/XMLSchema#string

P921